Biopharma GettyImages-1298364833.jpg
Our Work

Latham & Watkins Advises on ArriVent’s Upsized Initial Public Offering

January 26, 2024
Firm represents the underwriters in the IPO.

ArriVent BioPharma, Inc. (ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, has announced the pricing of its upsized initial public offering of 9,722,222 shares of its common stock at a public offering price of US$18 per share. All of the shares of common stock are being offered by ArriVent. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by ArriVent, are expected to be approximately US$175 million. ArriVent’s common stock are expected to begin trading on the Nasdaq Global Market on January 26, 2024 under the ticker symbol “AVBP.” The offering is expected to close on January 30, 2024, subject to the satisfaction of customary closing conditions. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

Latham & Watkins advised the underwriters in the offering, with a capital markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Roger Yarett, Jie Lin Nai, and Richard Dacher.